26 November 2020
EMA/634109/2020
Human Medicines Evaluation Division

List of nationally authorised medicinal products

Active substance: lamivudine / tenofovir disoproxil

Procedure no.: PSUSA/00010751/202003

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Product Name (in authorisation country)	MRP/DCP Authorisation number	National Authorisation Number	MAH of product in the member state	Member State where product is authorised
Lamivudine/Tenofovir disoproxil 300 mg/245 mg film-coated tablets	DE/H/5651/001	PL 36390/0217	CIPLA (EU) LIMITED	UK
Lamivudină/Tenofovir disoproxil Cipla 300 mg/245 mg comprimate filmate	DE/H/5651/001	10584/2018/01	CIPLA EUROPE NV	RO
Lamivudină/Tenofovir disoproxil Cipla 300 mg/245 mg comprimate filmate	DE/H/5651/001	10584/2018/02	CIPLA EUROPE NV	RO
Lamivudină/Tenofovir disoproxil Cipla 300 mg/245 mg comprimate filmate	DE/H/5651/001	10584/2018/03	CIPLA EUROPE NV	RO
Lamivudină/Tenofovir disoproxil Cipla 300 mg/245 mg comprimate filmate	DE/H/5651/001	10584/2018/04	CIPLA EUROPE NV	RO
Lamivudin/Tenofovirdisoproxil Cipla 300/245 mg Filmtabletten	DE/H/5651/001	97614.00.00	CIPLA EUROPE NV	DE
Lamivudina/Tenofovir disoproxilo Cipla 300 mg/245 mg comprimidos recubiertos con película.	DE/H/5651/001	83802	CIPLA EUROPE NV	ES